CEL-SCI (NYSE:CVM) Now Covered by StockNews.com

StockNews.com started coverage on shares of CEL-SCI (NYSE:CVM) in a report released on Friday morning. The firm issued a sell rating on the stock.

CEL-SCI Trading Up 6.1 %

Shares of CVM stock opened at $0.42 on Friday. The stock has a 50 day simple moving average of $0.55 and a 200 day simple moving average of $0.89. CEL-SCI has a 1 year low of $0.36 and a 1 year high of $3.08. The company has a current ratio of 1.31, a quick ratio of 1.09 and a debt-to-equity ratio of 0.62. The stock has a market cap of $30.76 million, a P/E ratio of -0.81 and a beta of 0.65.

Institutional Trading of CEL-SCI

Institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC raised its stake in CEL-SCI by 29.9% during the second quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock worth $202,000 after acquiring an additional 40,000 shares in the last quarter. Calton & Associates Inc. acquired a new position in CEL-SCI during the 3rd quarter worth approximately $50,000. Geode Capital Management LLC lifted its stake in CEL-SCI by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after purchasing an additional 53,879 shares during the last quarter. Finally, Plotkin Financial Advisors LLC acquired a new stake in shares of CEL-SCI during the 3rd quarter valued at $98,000. Institutional investors own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.